No abstract

BACKGROUND: Multisystem inflammatory syndrome (MIS) associated with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is a lifethreatening condition first described in children (MIS-C). It is characterized by a hyperinflammatory state that involves the cardiovascular, gastrointestinal, dermatologic, and neurologic systems without severe respiratory system involvement. Myocarditis is one of the cardiovascular presentations of MIS that might be complicated with cardiogenic shock. There are few case reports describing SARS-CoV-2-related MIS in adults (MIS-A).

Given recent advances in the treatment of cancer, patients are surviving longer but frequently develop treatment‐resistant and inoperable metastases. Biomedical research has advanced to the stage where in‐depth study of these lesions is feasible, with the goal of further refining our understanding of metastatic dissemination, therapeutic resistance and inoperable tumors. However, there is a lack of tissue specimens derived from multiple metastatic sites within the same patient that would permit the study of these processes. Furthermore, patients with rapidly progressing or metastatic disease are rarely candidates for surgery, making those most in need of innovation and discovery extremely difficult to study. For this reason, post‐mortem tissue donation programs are an approach that is quickly gaining traction in the cancer research community. Herein, we discuss what post‐mortem tissue donation entails, attitudes towards these procedures, and highlight important studies already utilizing these resources. In addition, we propose future directions for use of this tissue that can directly improve clinical management of advanced cancer patients.

Background  In the early developmental phase of a postmortem rapid tissue donation (RTD) program for patients with metastatic cancer, we surveyed health care professionals (HCPS) and oncology patients at the McGill University Health Centre (MUHC) to assess their knowledge and attitudes pertaining to RTD from metastatic cancer patients for research purposes.Methods   A 23-item survey was developed and distributed to hcps at tumour board meetings, and a related 26-item survey was developed and distributed to oncology patients at the MUHC Cedars Cancer Centre.Results   The survey attracted participation from 73 HCPS, including 37 attending physicians, and 102 oncology patients. Despite the fact that 88% of hcps rated their knowledge of RTD as none or limited, 42% indicated that they would feel comfortable discussing RTD with their cancer patients. Of the responding hcps, 67% indicated that their current knowledge of RTD would affect their decision to discuss such a program with patients, which implies the importance of education for hcps to facilitate enrolment of patients into a RTD program. Of responding patients, 78% indicated that they would not be uncomfortable if their doctor discussed RTD with them, and 61% indicated that they would like it if their doctor were to discuss RTD with them. The hcps and patients felt that the best time for patients to be approached about consenting to a RTD program would be at the transition to palliative care when no treatment options remain.Conclusions   At the MUHC, hcps and patients are generally enthusiastic about adopting a RTD program for patients with metastatic cancer. Education of hcps and patients will be an important determinant of the program’s success.